{
  "metadata": {
    "creation_date": "2025-01-05",
    "description": "20-ticker pilot from Wake Robin 281-ticker universe",
    "source": "Major biotech indices (XBI, IBB, NBI)",
    "selection_criteria": "Mix of commercial-stage and clinical-stage companies with active catalysts"
  },
  "tickers": [
    {
      "ticker": "ARGX",
      "company": "argenx SE",
      "stage": "commercial",
      "primary_indication": "Autoimmune disorders",
      "market_cap_tier": "large"
    },
    {
      "ticker": "INCY",
      "company": "Incyte Corporation",
      "stage": "commercial",
      "primary_indication": "Oncology/Hematology",
      "market_cap_tier": "large"
    },
    {
      "ticker": "JAZZ",
      "company": "Jazz Pharmaceuticals",
      "stage": "commercial",
      "primary_indication": "Sleep disorders/Oncology",
      "market_cap_tier": "large"
    },
    {
      "ticker": "IONS",
      "company": "Ionis Pharmaceuticals",
      "stage": "commercial",
      "primary_indication": "Rare diseases",
      "market_cap_tier": "mid"
    },
    {
      "ticker": "BBIO",
      "company": "BridgeBio Pharma",
      "stage": "commercial",
      "primary_indication": "Rare diseases",
      "market_cap_tier": "mid"
    },
    {
      "ticker": "GOSS",
      "company": "Gossamer Bio",
      "stage": "phase_3",
      "primary_indication": "Autoimmune",
      "market_cap_tier": "small"
    },
    {
      "ticker": "RNA",
      "company": "Avidity Biosciences",
      "stage": "phase_3",
      "primary_indication": "Muscle diseases",
      "market_cap_tier": "small"
    },
    {
      "ticker": "KYMR",
      "company": "Kymera Therapeutics",
      "stage": "phase_2",
      "primary_indication": "Immunology/Oncology",
      "market_cap_tier": "small"
    },
    {
      "ticker": "RYTM",
      "company": "Rhythm Pharmaceuticals",
      "stage": "commercial",
      "primary_indication": "Rare genetic obesity",
      "market_cap_tier": "small"
    },
    {
      "ticker": "EPRX",
      "company": "Eupraxia Pharmaceuticals",
      "stage": "phase_2",
      "primary_indication": "Pain management",
      "market_cap_tier": "micro"
    },
    {
      "ticker": "ACAD",
      "company": "ACADIA Pharmaceuticals",
      "stage": "commercial",
      "primary_indication": "CNS disorders",
      "market_cap_tier": "mid"
    },
    {
      "ticker": "ALNY",
      "company": "Alnylam Pharmaceuticals",
      "stage": "commercial",
      "primary_indication": "RNAi therapeutics",
      "market_cap_tier": "large"
    },
    {
      "ticker": "BMRN",
      "company": "BioMarin Pharmaceutical",
      "stage": "commercial",
      "primary_indication": "Rare genetic diseases",
      "market_cap_tier": "large"
    },
    {
      "ticker": "CRSP",
      "company": "CRISPR Therapeutics",
      "stage": "commercial",
      "primary_indication": "Gene editing",
      "market_cap_tier": "mid"
    },
    {
      "ticker": "VRTX",
      "company": "Vertex Pharmaceuticals",
      "stage": "commercial",
      "primary_indication": "Cystic fibrosis",
      "market_cap_tier": "mega"
    },
    {
      "ticker": "SRPT",
      "company": "Sarepta Therapeutics",
      "stage": "commercial",
      "primary_indication": "Duchenne muscular dystrophy",
      "market_cap_tier": "mid"
    },
    {
      "ticker": "UTHR",
      "company": "United Therapeutics",
      "stage": "commercial",
      "primary_indication": "Pulmonary arterial hypertension",
      "market_cap_tier": "mid"
    },
    {
      "ticker": "EXEL",
      "company": "Exelixis",
      "stage": "commercial",
      "primary_indication": "Oncology",
      "market_cap_tier": "mid"
    },
    {
      "ticker": "RARE",
      "company": "Ultragenyx Pharmaceutical",
      "stage": "commercial",
      "primary_indication": "Rare diseases",
      "market_cap_tier": "mid"
    },
    {
      "ticker": "FOLD",
      "company": "Amicus Therapeutics",
      "stage": "commercial",
      "primary_indication": "Rare diseases",
      "market_cap_tier": "mid"
    }
  ],
  "validation": {
    "total_count": 20,
    "commercial_stage": 15,
    "clinical_stage": 5,
    "coverage_target": "100% price data, 80% financial data, 60% trial data"
  }
}
